Breast Augmentation in Indonesia
Breast Augmentation plastic surgery in Indonesia section, includes general infrmation about Breast Augmentation Procedure, Breast Augmentation Indonesia Local News, Breast Augmentation Indonesia Surgeon Locator and other breast augmentation related materal.
Indonesia Breast Augmentation - The Plastic Surgery Procedure
The plastic surgery operation is usually done when the breast reaches its final size after puberty (ages 17-18). Except for cases when there is congenital breast hypoplasia or breast asymmetry in which it can be done earlier (local regulations in Indonesia may be applicable).
Indonesia breast augmentation - the implants
There are three possible areas for the insertion of an implant for augmentation. The lower fold of the breast is the most common site. It allows full excess and lives a hidden scar. The second site is through the areola. This incision gives the best esthetic results but it is also the only one that goes through the breast tissue therefore the risk of infection and sensation loss is higher. The third one is through the armpits. Some plasit surgeons prefer it because the scar is almost invisible (except for those women who like to wear open close with no sleeves(. The disadvantage of this incision is a slight asymmetry of the breast. The decision usually made individually with each woman and the plastic surgeon (consult local Indonesia surgeons).
The augmentation implant can be inserted above or below the chest muscles. The below position considered to be more preferable by most Indonesia surgeons. There is less chance of feeling the implant, less chance of developing irregular folds or bumps on the surface of the breast and the implant is less likely to drop. This kind of plastic surgery technique is suitable for women with relatively little extra skin and less fallen breasts.
Most of the implants are made of silicon, and since the FDA determined that they safe for use they are being widely used by most plastic surgeons in Indonesia.
[breast augmentation Indonesia top]
Indonesia breast augmentation - shape and size
The augmentation implants come in two shapes: round and pear shape also called "anatomic implants" because their shape resembles the natural contour of the breast. They are more expensive and require larger excision during the breast augmentation plastic surgery procedure.
The size of an implant usually depends on the woman size and proportions, the average size is 300cc. It is believed that smaller implants have lower complications.
[breast augmentation Indonesia top]
Indonesia breast augmentation - after the plastic surgery
After the augmentation plastic surgery you'll be wearing a sports bra or a bandage. You'll continue wearing them at all times day and night for about a month. You'll be able to take a shower 24 hours after the plastic surgery. The most optimal results usually seen 3 month after the surgery. Several things can complicate this plastic surgery procedure; those are rare complications, which you should be aware off. Bleeding around the area of the implant, infection, disturbances of sensation and touch around the nipples, silicon leak, rejection off an implant and some degree of irregularity on the surface of an implant.
Other Breast Augmentation Procedures
All Breast Plastic Surgery Procedures
Indonesia Breast augmentation Plastic Surgery (current)
Indonesia Breast Lift Plastic Surgery
Indonesia Breast Implants Plastic Surgery
Indonesia Implant Removal Plastic Surgery
Indonesia Armpit Incision Plastic Surgery
More Indonesia info...
Indonesia Climate Upon arrival and disembarking from the plane, one immediately notices the sudden rush of warm, wet air. Indonesia is a warm place. It has no spring, summer, fall, or winter, just two seasons: rainy and dry, both of which are relative (it still rains during the dry season, it just rains less). While there is significant regional variation, in most of the country (including Java and Bali) the dry season is April to October, while the wet season is November to March.
Indonesia Visa-free entry Nationals of Thailand, Malaysia, Singapore, Brunei, Philippine, Hong Kong SAR, Macao SAR, Chile, Morocco, Peru and Vietnam are given visa-free entry facility for maximum of 30 days. They cannot entend their stay and cannot convert their visa-free status to any other visa status.
Visa-free entries are only permitted via the following ports of entry:
Airports: Adi Juanda (Surabaya, East Java), Adi Sumarno (Solo, Central Java), El Tari (Kupang, West Timor), Hang Nadim (Batam, Riau Islands), Hasanuddin (Makasar, South Sulawesi), Husein Sastranegara (Bandung, West Java), Ngurah Rai (Denpasar, Bali), Polonia (Medan, North Sumatra), Sam Ratulangi (Manado, North Sulawesi), Selaparang (Mataram, Lombok), Sepinggan (Balikpapan, East Kalimantan), Soekarno Hatta (Jakarta), Sultan Syarif Kasim II or Simpang Tiga (Pekanbaru, Riau), Supadio (Pontianak, West Kalimantan) and Minangkabau International Airport (Padang, West Sumatera).
Breast AugmentationLatest Forum Posts...
- The British Association of Aesthetic Plastic Surgeons,The not-for-profit organisation established for the advancement of education and practice of Aesthetic Plastic Surgery for public benefit, denounced a website offering free breast augmentations as ‘degrading’ and warned British women that the process was entirely inappropriate for what should be a life-changing decision.
The BAAPS have learned that UK women are being lured into joining the ‘myfreeimplants.com’ site, where they post photos of themselves and a personal profile, meant to entice men to donate money to pay for their breast augmentation surgery.
Plastic Surgery News...
- According to research published in the Journal of the American Medical Association, there were no significant differences in clinical outcomes between patients receiving sirolimus- and paclitaxel-eluting stents in everyday clinical practice.
Researchers evaluated sirolimus- and paclitaxel-eluting stents for the prevention of symptom-driven clinical end points, using a study design reflecting everyday clinical practice. The SORT OUT II trial involved 2098 patients treated with percutaneous coronary intervention (PCI) and randomised to receive either sirolimus-eluting (n = 1065) or paclitaxel-eluting (n = 1033) stents. Indications for PCI included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina. Additionally, dual antiplatelet therapy with aspirin and clopidogrel was recommended for 1 year for all patients. After that period, clopidogrel was discontinued and aspirin continued lifelong, if tolerated.
The primary end point was a composite clinical end point of major adverse cardiac events, defined as either cardiac death, acute myocardial infarction, target lesion revascularisation, or target vessel revascularisation. Secondary end points were individual components of the composite end point, all-cause mortality and stent thrombosis.
The following results were reported:
• With respect to the primary end point, the sirolimus- and the paclitaxel-eluting stent groups did not differ significantly in major adverse cardiac events (98 [9.3%] vs. 114 [11.2%]; hazard ratio, 0.83 [95% confidence interval, 0.63-1.08]; P = 0.16)
• Additionally, no statistically significant differences were reported in stent thrombosis rates, rates of acute myocardial infarction, target lesion or vessel revascularisation, cardiac death or all-cause death
In a related editorial, the authors comment on possible limitations of the study:
1. The study randomised less than a third of the potentially eligible patients, which suggests that the cohort may not be as unselected as the authors had intended for emulating real life practice
2. The study was underpowered due to the small sample size coupled with relatively low event rates
- The U.S. Food and Drug Administration ssued an advisory strongly recommending that over-the-counter cough and cold medications not be given to infants and children under two years old because of the risk of life-threatening side effects.